We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





US ‘Operation Warp Speed’ To Ready 300 Million Vaccine Doses by End Of 2020

By HospiMedica International staff writers
Posted on 01 May 2020
The Trump administration is reportedly bringing biotech, pharma and federal agencies together in a project dubbed “Operation Warp Speed” that aims to cut the COVID-19 vaccine’s development time and deliver 100 million doses in the US by the end of the year.

The World Health Organization estimates more than 100 coronavirus vaccine candidates to be currently in development. More...
Experts do not expect a vaccine to be ready for at least 12 to 18 months. Under project “Operation Warp Speed”, pharmaceutical companies, government agencies and the military will work together to cut that time by up to eight months. The administration will help biopharma companies coordinate their individual efforts by providing assistance through federal agencies and the US military. The project is similar to the Manhattan Project-style joint initiative which brought different sectors together to develop the nation’s atomic bomb.

The officials are looking at a master trial protocol that would allow researchers to simultaneously study different vaccines instead of studying each vaccine separately through independent studies by pharmaceutical companies. The administration plans to speed up distribution by scaling up manufacturing capabilities as the vaccines enter large human trials. The goal of project “Operation Warp Speed” is to have 300 million doses of vaccine available by January.

In a media interview, Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases and a key member of the White House Coronavirus Task Force, said that developing a vaccine to combat the coronavirus outbreak by January was “doable.” Dr. Fauci said that it was possible to ready hundreds of millions of doses of a coronavirus vaccine by January. However, meeting the January deadline will ultimately depend upon whether the results of trials prove that the vaccine works.

“We're going to start ramping up production with the companies involved and you do that at risk, in other words you don't wait until you get an answer before you start manufacturing, you at risk, proactively, start making it, assuming it's going to work,” said Dr. Fauci. “And if it does, then you can scale up and hopefully get to that timeline.”


Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Gold Member
Blood Gas Analyzer
i-Check200
Gas Analyzer
GE SAM
Multi-Chamber Washer-Disinfector
WD 390
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The investigational niia signature wearable patch combines continuous glucose monitoring, insulin delivery, and automated glucose control in a single system. (photo courtesy of PharmaSens)

Wearable Patch Prototype Advances Toward Integrated Automated Insulin Delivery

Diabetes management requires individualized care, reliable glucose and ketone monitoring, and timely intervention. For automated insulin delivery, a key challenge is maintaining accurate glucose measurements... Read more

Patient Care

view channel
Image Credit: Adobe Stock

AI Platform Personalizes Support Between Visits for Cancer Survivors

Cancer survivors often manage persistent side effects after treatment, including fatigue, anxiety, uncertainty, symptoms, stress, and questions between appointments. Clinical teams need ways to maintain... Read more

Medical Imaging

view channel
Image: Visual Abstract (Andrea Farolfi et al., Journal of Nuclear Medicine, 2026. DOI: 10.2967/jnumed.126.272108)

PSMA PET/CT-Guided Biopsy Improves Detection of Significant Prostate Cancer After Nondiagnostic MRI

Prostate cancer can be difficult to detect when magnetic resonance imaging (MRI) findings are negative or inconclusive. Men with persistent clinical risk factors may still require biopsy, yet standard... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: WHX returns to Dubai Exhibition Centre, Expo City, and Dubai World Trade Centre from 5–28 January 2027 (Photo courtesy of World Health Expo)

World Health Expo to Showcase Trillion-Dollar Growth Across Pharma, Biotech, Longevity and Wellness at 2027 Edition

World Health Expo (WHX) expands with the new Pharma, Biotech, Longevity and Wellness industry sectors More than 235,000 professional visits, over 4,200 exhibitors and representatives from over... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.